A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

NCT00051116 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene Corporation